Literature DB >> 16698231

[Validation of the french translated Richmond vigilance-agitation scale].

G Chanques1, S Jaber, E Barbotte, R Verdier, K Henriette, J-Y Lefrant, J-J Eledjam.   

Abstract

OBJECTIVE: To test reliability of the Richmond Agitation Sedation Scale (RASS) after French translation. STUDY
DESIGN: Prospective psychomotor evaluation study. PATIENTS AND METHODS: Two bilingual physicians performed the translation from English to French language. The French version was then translated to English by a bilingual non physician ("backtranslation") and compared to the original version. The translated scale was tested according to usual guidelines concerning the translation of neuropsychological evaluation tools. The French version of RASS was tested on the morning of every fifth or sixth day, and 30-min after any procedure, in 43 consecutive patients admitted to a 12-bed medical-surgical intensive care unit during two months, by a group of four observers: the principal investigator, two anaesthesiology residents and one pharmacology student. Inter-rater reliability was tested using the simple and weighted Kappa coefficients (with their 95% confidence interval). A consensual and detailed "operating instructions" guide of RASS, intended for medical and nursing staff, has been added in the Annexe section.
RESULTS: Four hundred twenty measures were performed during 105 grouped observations. Reliability of the French version of RASS was substantial. Simple Kappa coefficient, testing the concordance between observers, was ranged from 0.72 (0.62-0.81) to 0.87 (0.79-0.94) and weighted Kappa coefficient from 0.95 (0.92-0.98) to 0.99 (0.98-0.99).
CONCLUSIONS: The French translation of RASS was acceptable. The translated scale preserved substantial inter-rater reliability. Monitoring of vigilance status in intensive care settings can be performed with this reliable clinical tool.

Entities:  

Mesh:

Year:  2006        PMID: 16698231     DOI: 10.1016/j.annfar.2006.02.017

Source DB:  PubMed          Journal:  Ann Fr Anesth Reanim        ISSN: 0750-7658


  11 in total

1.  Discomfort associated with underhumidified high-flow oxygen therapy in critically ill patients.

Authors:  Gerald Chanques; Jean-Michel Constantin; Magali Sauter; Boris Jung; Mustapha Sebbane; Daniel Verzilli; Jean-Yves Lefrant; Samir Jaber
Journal:  Intensive Care Med       Date:  2009-03-18       Impact factor: 17.440

2.  Assessing pain in non-intubated critically ill patients unable to self report: an adaptation of the Behavioral Pain Scale.

Authors:  Gérald Chanques; Jean-François Payen; Grégoire Mercier; Sylvie de Lattre; Eric Viel; Boris Jung; Moussa Cissé; Jean-Yves Lefrant; Samir Jaber
Journal:  Intensive Care Med       Date:  2009-12       Impact factor: 17.440

3.  Evaluation of the depth of sedation in an intensive care unit based on the photo motor reflex variations measured by video pupillometry.

Authors:  Ouri Rouche; Aurore Wolak-Thierry; Quentin Destoop; Lucas Milloncourt; Thierry Floch; Pascal Raclot; Damien Jolly; Joël Cousson
Journal:  Ann Intensive Care       Date:  2013-02-22       Impact factor: 6.925

4.  The 2014 updated version of the Confusion Assessment Method for the Intensive Care Unit compared to the 5th version of the Diagnostic and Statistical Manual of Mental Disorders and other current methods used by intensivists.

Authors:  Gérald Chanques; E Wesley Ely; Océane Garnier; Fanny Perrigault; Anaïs Eloi; Julie Carr; Christine M Rowan; Albert Prades; Audrey de Jong; Sylvie Moritz-Gasser; Nicolas Molinari; Samir Jaber
Journal:  Ann Intensive Care       Date:  2018-03-01       Impact factor: 6.925

5.  Multi-modal Educational Curriculum to Improve Richmond Agitation-sedation Scale Inter-rater Reliability in Pediatric Patients.

Authors:  Margaret J Kihlstrom; Ashley P Edge; Kelly M Cherry; Paul J Zarick; Shawna D Beck; Jenny M Boyd
Journal:  Pediatr Qual Saf       Date:  2018-08-07

6.  Sedation versus general anaesthesia in endovascular therapy for anterior circulation acute ischaemic stroke: the multicentre randomised controlled AMETIS trial study protocol.

Authors:  Russell Chabanne; Charlotte Fernandez-Canal; Vincent Degos; Anne-Claire Lukaszewicz; Lionel Velly; Segolene Mrozek; Pierre-François Perrigault; Serge Molliex; Benoit Tavernier; Claire Dahyot-Fizelier; Franck Verdonk; Elodie Caumon; Aurélie Masgrau; Marc Begard; Emmanuel Chabert; Anna Ferrier; Samir Jaber; Jean-Etienne Bazin; Bruno Pereira; Emmanuel Futier
Journal:  BMJ Open       Date:  2019-09-13       Impact factor: 2.692

7.  Incidence of Dexmedetomidine Withdrawal in Adult Critically Ill Patients: A Pilot Study.

Authors:  Rima H Bouajram; Krupa Bhatt; Rhiannon Croci; Laura Baumgartner; Kathleen Puntillo; James Ramsay; Ashley Thompson
Journal:  Crit Care Explor       Date:  2019-08-09

8.  Decreasing severe pain and serious adverse events while moving intensive care unit patients: a prospective interventional study (the NURSE-DO project).

Authors:  Audrey de Jong; Nicolas Molinari; Sylvie de Lattre; Claudine Gniadek; Julie Carr; Mathieu Conseil; Marie-Pierre Susbielles; Boris Jung; Samir Jaber; Gérald Chanques
Journal:  Crit Care       Date:  2013-04-18       Impact factor: 9.097

9.  Effect of a musical intervention on tolerance and efficacy of non-invasive ventilation in the ICU: study protocol for a randomized controlled trial (MUSique pour l'Insuffisance Respiratoire Aigue - Mus-IRA).

Authors:  Jonathan Messika; David Hajage; Nataly Panneckoucke; Serge Villard; Yolaine Martin; Emilie Renard; Annie Blivet; Jean Reignier; Natacha Maquigneau; Annabelle Stoclin; Christelle Puechberty; Stéphane Guétin; Aline Dechanet; Amandine Fauquembergue; Stéphane Gaudry; Didier Dreyfuss; Jean-Damien Ricard
Journal:  Trials       Date:  2016-09-13       Impact factor: 2.279

10.  Effects of dexmedetomidine on delirium duration of non-intubated ICU patients (4D trial): study protocol for a randomized trial.

Authors:  Clémence Louis; Thomas Godet; Gérald Chanques; Nathalie Bourguignon; Dominique Morand; Bruno Pereira; Jean-Michel Constantin
Journal:  Trials       Date:  2018-06-04       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.